Development of Prodrug Type Circular siRNA for In Vivo Knockdown by Systemic Administration
Authors:
- 4 December 2020
- journal article
- research article
- Published by SAGE Publications in Nucleic Acid Therapeutics
- Vol. 30 (6) , 346-364
Abstract
SiRNAs are being developed as a novel therapeutic modality; however, problems impeding their application in extrahepatic tissues persist, including inadequate stability in biological environments and inefficient drug delivery system to target tissues. Thus, technological improvements that enable robust silencing of target messenger RNA (mRNA) in extrahepatic tissues are necessary. We developed prodrug type covalently closed siRNA (circular siRNA) as a novel nucleic acid agent to knockdown target genes in extrahepatic tissues by systemic administration without drug delivery components. Circular siRNA, which is chemically synthesizable, can assume optimal structures for efficient knockdown using its cleavable linker; namely, circular and linear structure in extracellular and intracellular environment, respectively. In this study, we investigated circular siRNA physicochemical properties, knockdown mechanism, and characteristics in vitro , as well as pharmacokinetics, accumulation, knockdown activity, and safety in vivo . Our circular siRNA exhibited higher stability against serum and exonucleases, increased cellular uptake, and stronger knockdown activity without transfection reagent in vitro than linear siRNA. Furthermore, after systemic administration to mice, circular siRNA showed prolonged circulation and improved knockdown activity in the liver, kidney, and muscle, without causing adverse effects. Circular siRNA may represent an additional platform for RNAi therapeutics, providing alternate solutions for disease treatment.Keywords
This publication has 53 references indexed in Scilit:
- Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated AmyloidosisCirculation, 2019
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisNew England Journal of Medicine, 2018
- Delivery of ENaC siRNA to epithelial cells mediated by a targeted nanocomplex: a therapeutic strategy for cystic fibrosisScientific Reports, 2017
- Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like CellsPLOS ONE, 2016
- An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary HyperoxaluriaJournal of the American Society of Nephrology, 2016
- Targeted fibrillar nanocarbon RNAi treatment of acute kidney injuryScience Translational Medicine, 2016
- An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophiliaNature Medicine, 2015
- Novel Hydrophobically Modified Asymmetric RNAi Compounds (sd-rxRNA) Demonstrate Robust Efficacy in the EyeJournal of Ocular Pharmacology and Therapeutics, 2013
- Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAsNature, 2004
- Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cellsNature, 2001